Clinical implications of immune reconstitution following hematopoietic stem cell transplantation

Karl S. Peggs, Aviva C. Krauss, Crystal L. MacKall

Research output: Contribution to journalArticle

Abstract

The evolution of understanding regarding key issues involved in immune reconstitution should allow movement from indirect supportive care of immuno-incompetence following HSCT to proactive measures designed to enhance reconstitution in this setting. Future clinical studies using lymphoid progenitors, thymoprotective agents and immunostimulatory cytokines are needed to test the clinical utility of these approaches and agents which have had promising results in preclinical models. Importantly, while solid pre-clinical supporting data exist for many agents and approaches, clinical application mustproceed carefully, with particular attention to issues that may depend critically on timing and dose. Allogeneic HSCT presents a challenging arena for the application of immune based therapies because of the need to respect the delicate balance between GvHD, GvT responses, rejection and reconstitution of specific immunity against pathogens. Armed with our current and rapidly evolving knowledge, it is hopes that the coming years will witness the evolutionary development of clinical practice in this arena.

Original languageEnglish (US)
Pages (from-to)131-154
Number of pages24
JournalCancer Treatment and Research
Volume144
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Immunity
Cytokines
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical implications of immune reconstitution following hematopoietic stem cell transplantation. / Peggs, Karl S.; Krauss, Aviva C.; MacKall, Crystal L.

In: Cancer Treatment and Research, Vol. 144, 2009, p. 131-154.

Research output: Contribution to journalArticle

Peggs, Karl S. ; Krauss, Aviva C. ; MacKall, Crystal L. / Clinical implications of immune reconstitution following hematopoietic stem cell transplantation. In: Cancer Treatment and Research. 2009 ; Vol. 144. pp. 131-154.
@article{2176c940b112462c8b92db6048ecca25,
title = "Clinical implications of immune reconstitution following hematopoietic stem cell transplantation",
abstract = "The evolution of understanding regarding key issues involved in immune reconstitution should allow movement from indirect supportive care of immuno-incompetence following HSCT to proactive measures designed to enhance reconstitution in this setting. Future clinical studies using lymphoid progenitors, thymoprotective agents and immunostimulatory cytokines are needed to test the clinical utility of these approaches and agents which have had promising results in preclinical models. Importantly, while solid pre-clinical supporting data exist for many agents and approaches, clinical application mustproceed carefully, with particular attention to issues that may depend critically on timing and dose. Allogeneic HSCT presents a challenging arena for the application of immune based therapies because of the need to respect the delicate balance between GvHD, GvT responses, rejection and reconstitution of specific immunity against pathogens. Armed with our current and rapidly evolving knowledge, it is hopes that the coming years will witness the evolutionary development of clinical practice in this arena.",
author = "Peggs, {Karl S.} and Krauss, {Aviva C.} and MacKall, {Crystal L.}",
year = "2009",
doi = "10.1007/978-0-387-78580-6-6",
language = "English (US)",
volume = "144",
pages = "131--154",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Clinical implications of immune reconstitution following hematopoietic stem cell transplantation

AU - Peggs, Karl S.

AU - Krauss, Aviva C.

AU - MacKall, Crystal L.

PY - 2009

Y1 - 2009

N2 - The evolution of understanding regarding key issues involved in immune reconstitution should allow movement from indirect supportive care of immuno-incompetence following HSCT to proactive measures designed to enhance reconstitution in this setting. Future clinical studies using lymphoid progenitors, thymoprotective agents and immunostimulatory cytokines are needed to test the clinical utility of these approaches and agents which have had promising results in preclinical models. Importantly, while solid pre-clinical supporting data exist for many agents and approaches, clinical application mustproceed carefully, with particular attention to issues that may depend critically on timing and dose. Allogeneic HSCT presents a challenging arena for the application of immune based therapies because of the need to respect the delicate balance between GvHD, GvT responses, rejection and reconstitution of specific immunity against pathogens. Armed with our current and rapidly evolving knowledge, it is hopes that the coming years will witness the evolutionary development of clinical practice in this arena.

AB - The evolution of understanding regarding key issues involved in immune reconstitution should allow movement from indirect supportive care of immuno-incompetence following HSCT to proactive measures designed to enhance reconstitution in this setting. Future clinical studies using lymphoid progenitors, thymoprotective agents and immunostimulatory cytokines are needed to test the clinical utility of these approaches and agents which have had promising results in preclinical models. Importantly, while solid pre-clinical supporting data exist for many agents and approaches, clinical application mustproceed carefully, with particular attention to issues that may depend critically on timing and dose. Allogeneic HSCT presents a challenging arena for the application of immune based therapies because of the need to respect the delicate balance between GvHD, GvT responses, rejection and reconstitution of specific immunity against pathogens. Armed with our current and rapidly evolving knowledge, it is hopes that the coming years will witness the evolutionary development of clinical practice in this arena.

UR - http://www.scopus.com/inward/record.url?scp=77953677957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953677957&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-78580-6-6

DO - 10.1007/978-0-387-78580-6-6

M3 - Article

C2 - 19779871

AN - SCOPUS:77953677957

VL - 144

SP - 131

EP - 154

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -